Survivin、PTEN和Livin在皮肤基底细胞癌中的表达及三氧化二砷对其的影响
|
摘要
目的:随着社会老龄化,皮肤肿瘤发病率逐渐升高,其中表皮细胞肿瘤如皮肤基底细胞癌和皮肤鳞状细胞癌以及脂溢性角化病等最常见,对人类健康造成威胁。因而,探讨科学有效的治疗方法具有重要的临床意义和社会意义。
Survivin是凋亡蛋白抑制因子(inhibitor of apoptosis proteins, IAPs)家族的新成员,特异表达于人和鼠的胚胎发育组织和多数人类肿瘤。Survivin基因定位于染色体17q25,全长125 kb,由四个外显子和三个内含子组成,mRNA1,619nt,编码的蛋白含142个氨基酸残基,分子量为16.5Kda,是IAP基因家族的最小成员。由于Survivin在肿瘤组织中的特异表达及其在抑制细胞凋亡作用和调节细胞分裂中的重要作用,使其成为一个具有潜在应用价值的肿瘤标志物和肿瘤治疗的新靶点。
PTEN基因是迄今为止发现的第一个具有双特异性磷酸源性的抑癌基因,在维持细胞的增殖分裂和凋亡的平衡中起重要作用,在多种恶性肿瘤中发生突变或丧失,导致其抑癌功能减弱或丧失,在多种恶性肿瘤的发生、发展中起重要作用。对PTEN基因的研究将为恶性肿瘤的早期诊断、临床监测、基因靶向治疗、预后评估、新药研发和一级预防提供科学的理论依据。
Livin基因是最近发现的一个凋亡蛋白抑制因子(inhibitor of apoptosis protein IAP)家族的一个成员,该基因位于人染色体20q13.3,全长4.6kb,包含7个外显子,基因转录产物mRNA长1.4kb。有研究认为Livin既在胞质内呈丝状表达,同时也表达于胞核,并认为LivinC末端的RING结构对介导其在亚细胞水平上的分布有重要作用。有研究证实Livin mRNA在人多种类型的肿瘤细胞系中高表达,可能与人某些类型肿瘤的形成存在密切关系。
上世纪中后期,我国学者使用三氧化二砷治疗急性早幼粒白血病取得显著疗效,未出现严重不良反应。研究还表明三氧化二砷可以诱导多种实体瘤细胞生长阻值和凋亡,三氧化二砷抗实体瘤具有如下机制:三氧化二砷可诱导肿瘤细胞分化,改变其恶性特征;三氧化二砷以蛋白巯基为直接作用靶点,改变和影响酶的活性,继而引起一系列的抗癌效应;三氧化二砷通过线粒体途径诱导肿瘤细胞凋亡;活性氧化物在三氧化二砷诱导凋亡中起作用;三氧化二砷可以抑制端粒酶活性,可达到抑制肿瘤的目的。2004年9月,我国食品药品管理监督局批准三氧化二砷注射液可用于晚期原发性肝癌的治疗。但三氧化二砷对实体瘤的治疗作用和抗肿瘤机制仍未明确。
在此基础上,本研究拟观察与细胞凋亡密切相关的Survivin基因,PTEN,和Livin等在皮肤基底细胞癌中的表达情况,探讨皮肤基底细胞癌发生、发展的病理机制,并初步探讨三氧化二砷对皮肤基底细胞癌细胞增殖的影响,观察对皮肤基底细胞癌细胞株Survivin表达的抑制或影响,企图为应用三氧化二砷治疗皮肤基底细胞癌提供理论和实验室依据。
方法:
1 Survivin和PTEN在皮肤基底细胞癌中的表达的研究
选取2005年11月-2007年11月我科就疹的皮肤肿瘤患者:皮肤基底细胞癌30例,其中男性18例,女性12例,年龄45-83岁,平均年龄67.40岁;部位:颜面部12例;头皮部:9例;躯干部:6例;四肢3例;病程12个月~15年,平均36.6个月。脂溢性角化病30例,其中棘层肥厚型13例,角化过度型8例,巢状型4例,腺样型3例,刺激型2例;男性16例,女性14,年龄38岁-70岁,平均年龄54.8岁。正常皮肤组织20例,男13例,女7例,年龄17~68岁,均来自我科手术患者,年龄、部位与患者组相匹配。常规组织学技术观察表皮肿瘤的病理特点;并运用免疫组织化学技术、流式细胞术技术观察Survivin和PTEN基因在皮肤基底细胞癌中蛋白水平表达及相关性情况,进一步探讨Survivin和PTEN基因在皮肤基底细胞癌发病及发展中的作用。
2 Livin蛋白在基底细胞癌中的表达及其与survivin的相关性分析
收集标本同第一部分,运用免疫组化、流式细胞术观察Livin在皮肤基底细胞癌和脂溢性角化等表皮肿瘤中的蛋白水平表达情况。并分析Livin蛋白与皮肤基底细胞癌发生、发展的关系。并在第一部分的基础上,分析Livin蛋白与survivin蛋白表达之间的相关性,了解二者在表皮肿瘤发病过程中的相互关系。分析Livin蛋白与PTEN蛋白表达之间的相关性,了解二者在皮肤基底细胞癌发病过程中的相互关系。并观察Livin蛋白表达与皮肤基底细胞癌临床病理特征之间的关系。
3三氧化二砷对人基底细胞癌细胞株A-431增殖及相关基因表达的影响
常规培养皮肤基底细胞癌细胞株A-431,加入不同浓度的三氧化二砷,采用MTT法观察不同浓度的As2O3对A431细胞增殖在不同时间点(0h、24h、48h、72h)的影响,应用流式细胞仪检测三氧化二砷对A-431细胞细胞周期、凋亡和Survivin等基因表达的变化。应用Western Blot免疫印迹技术观察三氧化二砷对A-431细胞Survivin基因表达的影响。观察不同浓度的三氧化二砷对培养的皮肤基底细胞癌细胞株增殖的影响,观察对Survivin基因蛋白水平表达的影响。
结果:
1 Survivin和PTEN在皮肤基底细胞癌中的表达及与临床病理特征之间关系
(1)免疫组化结果显示,在30例脂溢性角化病皮损中,19例中Survivin蛋白阳性表达,正常20例皮肤组织中均为阴性表达,差异有显著性(P<0.05);30例脂溢性角化病皮损中,16例PTEN蛋白阳性表达,正常20例皮肤组织中14例有PTEN表达,二者比较差异无显著性(P>0.05)。
(2)在基底细胞癌中,Survivin蛋白的表达高于在正常皮肤组织(P<0.05)和脂溢性角化病(P<0.05)中的表达;而PTEN蛋白的表达则低于在正常皮肤组织(P<0.05)和脂溢性角化病(P<0.05)中的表达。
(3)相关性分析发现,Survivin和PTEN蛋白在SK、BCC等表皮良恶性肿瘤中的表达呈显著负相关(P<0.05)。随肿瘤恶性度逐渐增高,Survivin表达逐渐升高,而PTEN表达逐渐下降。
(4)在基底细胞癌组中,Survivin在年龄>60岁组中的表达高于在年龄≤60岁组中的表达,两组之间表达差异有显著性(P<0.05);PTEN在年龄>60岁组中的表达低于在年龄≤60岁组中的表达,两组之间表达差异有显著性(P<0.05)。Survivin在皮损平均直径>2cm组中的表达高于在皮损平均直径≤2cm组中的表达(P<0.05);PTEN在皮损平均直径>2cm组中的表达低于在皮损平均直径≤2cm组中的表达(P<0.05)。Survivin在病程>平均病程组中的表达高于在病程≤平均病程组中的表达(P<0.05)而PTEN在病程>平均病程组中的表达低于在病程≤平均病程组中的表达(P<0.05)。Survivin和PTEN在基底细胞癌中的表达与患者性别、发病部位、皮损数目无关(P>0.05)。
2 Livin蛋白在皮肤基底细胞癌中的表达及其与Survivin的相关性分析
(1)免疫组化染色结果
Livin蛋白表现为细胞浆着色,在30例基底细胞癌中,26例中有明显的表达(阳性率86.67%),而30例脂溢性角化病组中有16例有阳性表达(阳性率53.33%),20例正常对照组织中仅见1例有弱阳性表达(阳性率5.00%)。Livin蛋白在基底细胞癌组中的表达阳性率明显高于在脂溢性角化病组的表达,两者比较差异有显著性(P<0.05);同时也高于在正常皮肤组中的表达,两者比较差异有显著性(P<0.05)。Livin蛋白在脂溢性角化病组织中的表达也高于在正常皮肤组中的表达,统计结果显示,差异有显著性(P<0.05)。从正常皮肤到脂溢性角化病到BCC,Livin蛋白的表达阳性率逐渐增高。Livin在年龄>60岁组中的表达高于在年龄≤60岁组中的表达,两组之间表达差异有显著性(P<0.05);Livin在皮损平均直径>2cm组中的表达高于在皮损平均直径≤2cm组中的表达(P<0.05);Livin在病程>平均病程组中的表达高于在病程≤平均病程组中的表达(P<0.05)。Livin在皮肤基底细胞癌中的表达与患者性别、发病部位、皮损数目无关(P>0.05)。
Spearmen秩相关检验相关性分析发现,在该组病例中,Livin蛋白和survivin蛋白表达之间存在正相关(r=0.557, P<0.05)。而Livin蛋白和PTEN蛋白表达之间存在负相关(r=-0.453, P<0.05)。
(2)流式细胞术定量检测Livin蛋白在皮肤基底细胞癌中表达的结果
在基底细胞癌组织中,Livin蛋白的免疫荧光均道值(586.75±33.73)明显高于脂溢性角化病(459.49±62.74),差异有显著性(P<0.05);同时也高于在正常组织中的免疫荧光均道值(327.57±98.37),差异有显著性(P<0.05);在脂溢性角化病组织中,Livin蛋白的免疫荧光均道值高于正常皮肤组织,两者比较差异有统计学意义(P<0.05)。从正常皮肤到脂溢性角化病到基底细胞癌,Livin蛋白的表达量的荧光均道值逐渐增高。
采用Person相关性分析发现,Livin蛋白和Survivin蛋白之间存在正相关(r=0.547, P<0.05);而Livin蛋白和PTEN蛋白表达之间存在负相关(r=-0.553, P<0.05)。与免疫组化的结果相一致。
3三氧化二砷对表皮癌细胞株A-431增殖、凋亡、细胞周期以及Survivin基因表达的影响
(1) MTT分析发现从浓度10umol/L到60umol/L,三氧化二砷可以显著地抑制A-431细胞的增殖,随着浓度的增加和时间的延长,OD值逐渐下降(P<0.05),该抑制过程呈时间依赖性和浓度依赖性。
(2)流式细胞术检测结果提示,As2O3影响A-431细胞周期的分布,不同浓度的As2O3作用A-431细胞后S期细胞群增多(P<0.05),存在S期阻滞;并且细胞凋亡数目增多(P<0.05)。
(3)与对照组比较,As2O3能抑制A431细胞survivin基因的表达,该蛋白表达量下降(P<0.05)。三氧化二砷对体外培养的皮肤基底细胞癌细胞株有显著的增殖抑制作用,有诱导表皮细胞癌凋亡作用;并可能与下调凋亡抑制基因Survivin的表达有关。
结论:
1本研究首次应用免疫组化和流式细胞术发现表皮肿瘤皮肤基底细胞癌和SK的发生发展可能与Survivin基因和PTEN基因的异常表达可能有关。联合检测这两种基因有助于判断基底细胞癌的预后和恶性程度的可能性。
2本研究首次应用流式细胞术和免疫组织化学的方法发现皮肤基底细胞癌的发生发展可能与凋亡抑制基因Livin的异常表达可能有关。Livin基因有可能成为皮肤基底细胞癌免疫治疗的靶基因。研究发现Livin和Survivin在皮肤基底细胞癌中的表达呈正相关,在皮肤基底细胞癌发病过程中二者之间可能存在协同作用。而Livin和PTEN在皮肤基底细胞癌中的表达呈负相关。
3本研究首次研究了三氧化二砷对体外培养的皮肤基底细胞癌细胞株增殖和survivin基因表达的影响,结果显示三氧化二砷对皮肤基底细胞癌细胞株有显著的增殖抑制作用,并且有诱导皮肤基底细胞癌细胞凋亡作用和细胞周期阻滞作用;该抑制过程并可能与下调凋亡抑制基因Survivin的表达和影响细胞周期分布有关。
Objectives:Epidermal tumors are ones of the most common malignant or benign tumors in the world. The incidence of basal cell carcinoma (BCC) and seborrheic keratosis (SK) is high in China.They are a great threaten to human health. Therefore, it is extremely important to investigate pathogenesis and search new target and effective drugs for BCC and SK therapy to decrease mortality and prolong life span of patients with epidermal tumors.
Survivin is a novel member of the apoptosis protein family member. Survivin has correlation with tumor development and progress in many human tumors. Its main biological functions include inhibiting cell apoptosis and enhancing cell proliferation. Survivin selectively expresses in most common hunman noeplasms. More and more researchers study it as an ideal target for cancer treatment. Down-regulation of survivin expression can induce cancer cell apoptosis and enhances radiosensitivity in many human cancers. It can be served as marker of prognosis.
PTEN is a dual-specificity lipid phosphase originally identified as a tumor suuressor gene. It frequently mutates and is absent in a number of human cancers, which leads to the weaking or absence of tumor suppressing functions. PTEN plays a critical role in the development and progression of many cancers. PTEN regulates complex signal transduction pathways (such as P13K/AKT pathway, FAK/MAPK cacade, PTEN/P53/MDM2 network), induces G1 cell-cycle arrest and apoptosis, suppresses the vscular formation and inhibits invasion and metastasis of tumors. With further study on the important function of PTEN, an earlier diagnosis, appropriate clinical surveillance, gene-targeted immunotherapy, prognostic evaluation, new drug development and population-oriented first-line prevention of cancers might be possible.
Livin, as a new member of IAPs, plays an important role in anti-cancers. Livin regulates complex signal transduction pathways (such as TAK1/JNK1, et al) in antiapoptotic functions. Many studies have discovered that livin protein and livin mRNA are expressed in many malignant human tumors, but not or down-regulatedly expressed in normal tissues and benign tumors. With further sdudy on the important functions of livin, it can be a gene target in immunotherapy for cancers.
Clinical trials have demonstrated that arsenic trioxide is effective for acute promyelocytic leukemia; it also has the action of induction of apoptosis and inhibition of growth of some solid cancer cells. It can induce differentiation of human nasopharyngeal carcinoma in BALB/C nude mice xenograft model. But the mechanisms are not clearly understood. Based on these facts, studies have been carried out to study its roles in the treatment of solid cancers. Many studies have discovered that arsenic trioxide can be used in many therapies for solid neoplasm.
Therefore, in the present study we examined the expression of survivin, PTEN proteins in the process of carcinogenesis of epidermal tumors and determined the correlation between the levels of these proteins and various clinical and pathological features. Then, we also examined the expression of livin in the process of carcinogenesis of BCC and SK and determined the correlation between the levels of these proteins and various clinical and pathological features;We also analysed the correlation between linvin and survivin, PTEN in BCC and SK. Next, we studied the effects of arsenic trioxide on proliferation, cell cycle distribution, and expression of survivin, PTEN and livin in human epidermal cancer A-431cells.It may deepen our knowledge about epidermal tumors such as basal cell carcinoma and Sk,et al.It might provide theoretical and experimental evidence for utilization of arsenic trioxide in epidermal carcinoma therapy.
Methods:
1 Expression of survivin, PTEN in epidermal tumors and normal skin tissues and the correlation between the levels of these proteins and clinical-pathological features.
Basal cell carcinoma tissues, seborrheic keratosis tissues and normal skin tissues were obtained from resected surgical specimens of epidermal tumors in our dermatology department. There were thirty cases of basal cell carcinoma including 18males and 12 females, who were aged from 45 to 83 years old (averaged 67.40 years old).There were 30 cases of SK including 16 males and 14 females, who were aged from 38 to 70 years old (averaged 54.80 years old).There were 20 cases of normal skin tissues which were from the patients who received surgical treatments in our dermatology department.
All the specimens were verified by pathologic diagnosis. Survivin, PTEN protein expression in normal skin tissues and the lesions of basal cell carcinoma and seborrheic keratosis were examined by immunohistochemistry (IHC). Survivin, PTEN protein expression in normal skin tissues and the lesions of basal cell carcinoma and seborrheic keratosis were also examined by flow cytometry (FCM). Relationship between their expressions and clinical pathological features was analyzed.
2 Expression of livin protein in epidermal tumors and normal skin tissues and the correlation between the levels of this protein and clinical-pathological features and the correlation with survivin and PTEN based on part one study.
In this study, basal cell carcinoma tissues, seborrheic keratosis tissues and normal skin tissues were obtained from resected surgical specimens of epidermal tumors in our dermatology department. All the specimens were verified by pathologic diagnosis. They were the same as in part one study. Livin protein expression in normal skin tissues and the lesions of basal cell carcinoma and seborrheic keratosis were examined by immunohistochemistry (IHC). Livin protein expression in normal skin tissues and the lesions of basal cell carcinoma and seborrheic keratosis were also examined by flow cytometry (FCM). Relationship between its expressions and clinical pathological features was analyzed. Statistical treatment with SPSS was applied to deal with all the experimental data.We also analysed the correlation with survivin and PTEN based on part one study.
3 Effects of arsenic trioxide on cell proliferation, apoptosis, cell cycle distribution and gene expression in human epidermis cancer cell line A-431
Human epidermal carcinoma cells (cell line A431) were conventionally cultured. After treatment with arsenic trioxide in different concentrations, inhibition of cellular growth was determined by measuring MTT dye absorption of living cells in 24,48,72h. We calculated the OD values.Then, apoptosis, cell cycle distribution and survivin expression were assessed by flow cytometry and western Blot methods.
Results:
1 Expression of survivin, PTEN in epidermal tumors and normal skin tissues and the correlation between the levels of these proteins and clinical-pathological features
(1) The protein of survivin was positively expressed in 18 cases of the 30 SK specimens while none was expressed in the 20 normal controls (P<0.05). The protein of PTEN was positively expressed in 17 cases of the 30 SK specimens and in 13 cases of the 20 normal controls (P>0.05).
(2) The protein of survivin was highly expressed in BCC lesions than in SK lesions and in normal controls (P<0.05), while the protein of PTEN was lowly expressed in BCC than in SK lesions and normal controls (P<0.05).
(3) There had been a significant negative correlation between the expressions of survivin and PTEN (r= -0.546, P<0.01) in BCC and SK.
(4) The expressions of survivin and PTEN were related with the patients’age, areas of the lesions and the disease duration (P<0.05), but not related with the patients’genders, sites of lesions and numbers of lesions (P>0.05) in patients with BCC.
2 Expression of livin protein in epidermal tumors and normal skin tissues and the correlation between the levels of this protein and clinical-pathological features and the correlation with survivin and PTEN.
(1) The protein of Livin was highly positively expressed in basal cell carcinoma than in seborrheic keratosis. There was significant difference (P<0.05) and it was also highlier expressed in BCC tissues than in normal controls (P<0.05).
(2) The protein of Livin was highlier expressed in SK lesions than in normal controls, there was significant difference (P<0.05).
(3) From normal skin to seborrheic keratosis and to basal cell carcinoma, the expressions of Livin were getting gradually highlier.
(4) The expressions of livin were related with the patients’age, areas of the lesions and the disease duration (P<0.05), but not related with the patients’gender, sites of lesions and numbers of lesions(P>0.05) in patients with basal cell carcinoma..
(5) There had been a significant positive correlation between the expressions of Livin and Survivin (r= 0.557, P<0.05) in basal cell carcinoma and seborrheic keratosis. There had been a significant positive correlation between the expressions of Livin and PTEN (r=- 0.453, P<0.05) in basal cell carcinoma and seborrheic keratosis.
3 Effects of arsenic trioxide on cell proliferation, apoptosis, cell cycle distribution and gene expression in human epidermis cancer cell A-431
MTT assay showed that with concentrations from 10umol/L to 40umol/L, arsenic trioxide can significantly inhibited the proliferation of A431 cells in a dose- and time-dependent manner (P<0.05). After A-431 cells were dealed with different concentration of arsenic trioxide in 24-72hours, the OD values of the treatment groups decreased to some extent compared with the control group. There were statistically significant differences between them. Survivin expression was significantly downed regulated by arsenic trioxide in A-431 cell line (P<0.05). Arsenic trioxide can inhibit cell proliferation and induce apoptosis in A-431 cells. Arsenic trioxide can also down-regulate the expression of Survivin in A-431 cells. The anti-proliferation effect of arsenic trioxide on human epidermoid carcinoma A-431 maybe is related to down-regulated expression of Survivin gene (P<0.05). Arsenic trioxide can also affect the cell cycle distribution in A-431 cells in our FCM assays. Every group of Arsenic trioxide blocked A-431 cell cycle at S-phase (P<0.05).
Cellular morphology was observed under light microscope: cells shrinkage after treatment, the breakdown was irregular in shapes. Pseudo-foot lenders appeared in some cells at both ends. A-431 cells showed morphological changes.
Conclusions:
(1)Our study found that in the process of carcinogenesis of the basal cell carcinoma, the expression of survivin may play a role in the pathgenesis of BCC and SK while the expression of PTEN may take a part in the protection of BCC and SK. There propably is an interaction between the two genes in BCC and SK. Detecting the two protein levels can provide certain reference value in evaluating the malignant probability and in judging the prognosis of seborrheic keratosis.
(2) It was first found that the abnormally high expressions of Livin protein may play a role in the pathogenesis of seborrheic keratosis and basal cell carcinoma through inhibiting cell apoptosis. From normal skin tissues to seberric kerotosis and to basal cell carcinoma, livin expressions are increasing gradually. Our study suggests that Livin can be a gene target in immunotherapy for epidermal tumors such as BCC and SK. There had been a significant positive correlation between the expressions of Livin and Survivin in BCC and SK.There may be a co-operation between the two genes in basal cell carcinoma and seborrheic keratosis. There had been a significant negtive correlation between the expressions of Livin and PTEN in BCC and SK.
(3) In our study, it was first found that arsenic trioxide can inhibit cell proliferation and induce apoptosis in A-431 cells. Arsenic trioxide can also down-regulate the expression of survivin in A-431 cells. The anti-proliferation effect of arsenic trioxide on human epidermoid carcinoma A-431 maybe is related to down-regulated expression of survivin gene. Arsenic trioxide can also affect the cell cycle distribution in A-431 cells.
Survivin是凋亡蛋白抑制因子(inhibitor of apoptosis proteins, IAPs)家族的新成员,特异表达于人和鼠的胚胎发育组织和多数人类肿瘤。Survivin基因定位于染色体17q25,全长125 kb,由四个外显子和三个内含子组成,mRNA1,619nt,编码的蛋白含142个氨基酸残基,分子量为16.5Kda,是IAP基因家族的最小成员。由于Survivin在肿瘤组织中的特异表达及其在抑制细胞凋亡作用和调节细胞分裂中的重要作用,使其成为一个具有潜在应用价值的肿瘤标志物和肿瘤治疗的新靶点。
PTEN基因是迄今为止发现的第一个具有双特异性磷酸源性的抑癌基因,在维持细胞的增殖分裂和凋亡的平衡中起重要作用,在多种恶性肿瘤中发生突变或丧失,导致其抑癌功能减弱或丧失,在多种恶性肿瘤的发生、发展中起重要作用。对PTEN基因的研究将为恶性肿瘤的早期诊断、临床监测、基因靶向治疗、预后评估、新药研发和一级预防提供科学的理论依据。
Livin基因是最近发现的一个凋亡蛋白抑制因子(inhibitor of apoptosis protein IAP)家族的一个成员,该基因位于人染色体20q13.3,全长4.6kb,包含7个外显子,基因转录产物mRNA长1.4kb。有研究认为Livin既在胞质内呈丝状表达,同时也表达于胞核,并认为LivinC末端的RING结构对介导其在亚细胞水平上的分布有重要作用。有研究证实Livin mRNA在人多种类型的肿瘤细胞系中高表达,可能与人某些类型肿瘤的形成存在密切关系。
上世纪中后期,我国学者使用三氧化二砷治疗急性早幼粒白血病取得显著疗效,未出现严重不良反应。研究还表明三氧化二砷可以诱导多种实体瘤细胞生长阻值和凋亡,三氧化二砷抗实体瘤具有如下机制:三氧化二砷可诱导肿瘤细胞分化,改变其恶性特征;三氧化二砷以蛋白巯基为直接作用靶点,改变和影响酶的活性,继而引起一系列的抗癌效应;三氧化二砷通过线粒体途径诱导肿瘤细胞凋亡;活性氧化物在三氧化二砷诱导凋亡中起作用;三氧化二砷可以抑制端粒酶活性,可达到抑制肿瘤的目的。2004年9月,我国食品药品管理监督局批准三氧化二砷注射液可用于晚期原发性肝癌的治疗。但三氧化二砷对实体瘤的治疗作用和抗肿瘤机制仍未明确。
在此基础上,本研究拟观察与细胞凋亡密切相关的Survivin基因,PTEN,和Livin等在皮肤基底细胞癌中的表达情况,探讨皮肤基底细胞癌发生、发展的病理机制,并初步探讨三氧化二砷对皮肤基底细胞癌细胞增殖的影响,观察对皮肤基底细胞癌细胞株Survivin表达的抑制或影响,企图为应用三氧化二砷治疗皮肤基底细胞癌提供理论和实验室依据。
方法:
1 Survivin和PTEN在皮肤基底细胞癌中的表达的研究
选取2005年11月-2007年11月我科就疹的皮肤肿瘤患者:皮肤基底细胞癌30例,其中男性18例,女性12例,年龄45-83岁,平均年龄67.40岁;部位:颜面部12例;头皮部:9例;躯干部:6例;四肢3例;病程12个月~15年,平均36.6个月。脂溢性角化病30例,其中棘层肥厚型13例,角化过度型8例,巢状型4例,腺样型3例,刺激型2例;男性16例,女性14,年龄38岁-70岁,平均年龄54.8岁。正常皮肤组织20例,男13例,女7例,年龄17~68岁,均来自我科手术患者,年龄、部位与患者组相匹配。常规组织学技术观察表皮肿瘤的病理特点;并运用免疫组织化学技术、流式细胞术技术观察Survivin和PTEN基因在皮肤基底细胞癌中蛋白水平表达及相关性情况,进一步探讨Survivin和PTEN基因在皮肤基底细胞癌发病及发展中的作用。
2 Livin蛋白在基底细胞癌中的表达及其与survivin的相关性分析
收集标本同第一部分,运用免疫组化、流式细胞术观察Livin在皮肤基底细胞癌和脂溢性角化等表皮肿瘤中的蛋白水平表达情况。并分析Livin蛋白与皮肤基底细胞癌发生、发展的关系。并在第一部分的基础上,分析Livin蛋白与survivin蛋白表达之间的相关性,了解二者在表皮肿瘤发病过程中的相互关系。分析Livin蛋白与PTEN蛋白表达之间的相关性,了解二者在皮肤基底细胞癌发病过程中的相互关系。并观察Livin蛋白表达与皮肤基底细胞癌临床病理特征之间的关系。
3三氧化二砷对人基底细胞癌细胞株A-431增殖及相关基因表达的影响
常规培养皮肤基底细胞癌细胞株A-431,加入不同浓度的三氧化二砷,采用MTT法观察不同浓度的As2O3对A431细胞增殖在不同时间点(0h、24h、48h、72h)的影响,应用流式细胞仪检测三氧化二砷对A-431细胞细胞周期、凋亡和Survivin等基因表达的变化。应用Western Blot免疫印迹技术观察三氧化二砷对A-431细胞Survivin基因表达的影响。观察不同浓度的三氧化二砷对培养的皮肤基底细胞癌细胞株增殖的影响,观察对Survivin基因蛋白水平表达的影响。
结果:
1 Survivin和PTEN在皮肤基底细胞癌中的表达及与临床病理特征之间关系
(1)免疫组化结果显示,在30例脂溢性角化病皮损中,19例中Survivin蛋白阳性表达,正常20例皮肤组织中均为阴性表达,差异有显著性(P<0.05);30例脂溢性角化病皮损中,16例PTEN蛋白阳性表达,正常20例皮肤组织中14例有PTEN表达,二者比较差异无显著性(P>0.05)。
(2)在基底细胞癌中,Survivin蛋白的表达高于在正常皮肤组织(P<0.05)和脂溢性角化病(P<0.05)中的表达;而PTEN蛋白的表达则低于在正常皮肤组织(P<0.05)和脂溢性角化病(P<0.05)中的表达。
(3)相关性分析发现,Survivin和PTEN蛋白在SK、BCC等表皮良恶性肿瘤中的表达呈显著负相关(P<0.05)。随肿瘤恶性度逐渐增高,Survivin表达逐渐升高,而PTEN表达逐渐下降。
(4)在基底细胞癌组中,Survivin在年龄>60岁组中的表达高于在年龄≤60岁组中的表达,两组之间表达差异有显著性(P<0.05);PTEN在年龄>60岁组中的表达低于在年龄≤60岁组中的表达,两组之间表达差异有显著性(P<0.05)。Survivin在皮损平均直径>2cm组中的表达高于在皮损平均直径≤2cm组中的表达(P<0.05);PTEN在皮损平均直径>2cm组中的表达低于在皮损平均直径≤2cm组中的表达(P<0.05)。Survivin在病程>平均病程组中的表达高于在病程≤平均病程组中的表达(P<0.05)而PTEN在病程>平均病程组中的表达低于在病程≤平均病程组中的表达(P<0.05)。Survivin和PTEN在基底细胞癌中的表达与患者性别、发病部位、皮损数目无关(P>0.05)。
2 Livin蛋白在皮肤基底细胞癌中的表达及其与Survivin的相关性分析
(1)免疫组化染色结果
Livin蛋白表现为细胞浆着色,在30例基底细胞癌中,26例中有明显的表达(阳性率86.67%),而30例脂溢性角化病组中有16例有阳性表达(阳性率53.33%),20例正常对照组织中仅见1例有弱阳性表达(阳性率5.00%)。Livin蛋白在基底细胞癌组中的表达阳性率明显高于在脂溢性角化病组的表达,两者比较差异有显著性(P<0.05);同时也高于在正常皮肤组中的表达,两者比较差异有显著性(P<0.05)。Livin蛋白在脂溢性角化病组织中的表达也高于在正常皮肤组中的表达,统计结果显示,差异有显著性(P<0.05)。从正常皮肤到脂溢性角化病到BCC,Livin蛋白的表达阳性率逐渐增高。Livin在年龄>60岁组中的表达高于在年龄≤60岁组中的表达,两组之间表达差异有显著性(P<0.05);Livin在皮损平均直径>2cm组中的表达高于在皮损平均直径≤2cm组中的表达(P<0.05);Livin在病程>平均病程组中的表达高于在病程≤平均病程组中的表达(P<0.05)。Livin在皮肤基底细胞癌中的表达与患者性别、发病部位、皮损数目无关(P>0.05)。
Spearmen秩相关检验相关性分析发现,在该组病例中,Livin蛋白和survivin蛋白表达之间存在正相关(r=0.557, P<0.05)。而Livin蛋白和PTEN蛋白表达之间存在负相关(r=-0.453, P<0.05)。
(2)流式细胞术定量检测Livin蛋白在皮肤基底细胞癌中表达的结果
在基底细胞癌组织中,Livin蛋白的免疫荧光均道值(586.75±33.73)明显高于脂溢性角化病(459.49±62.74),差异有显著性(P<0.05);同时也高于在正常组织中的免疫荧光均道值(327.57±98.37),差异有显著性(P<0.05);在脂溢性角化病组织中,Livin蛋白的免疫荧光均道值高于正常皮肤组织,两者比较差异有统计学意义(P<0.05)。从正常皮肤到脂溢性角化病到基底细胞癌,Livin蛋白的表达量的荧光均道值逐渐增高。
采用Person相关性分析发现,Livin蛋白和Survivin蛋白之间存在正相关(r=0.547, P<0.05);而Livin蛋白和PTEN蛋白表达之间存在负相关(r=-0.553, P<0.05)。与免疫组化的结果相一致。
3三氧化二砷对表皮癌细胞株A-431增殖、凋亡、细胞周期以及Survivin基因表达的影响
(1) MTT分析发现从浓度10umol/L到60umol/L,三氧化二砷可以显著地抑制A-431细胞的增殖,随着浓度的增加和时间的延长,OD值逐渐下降(P<0.05),该抑制过程呈时间依赖性和浓度依赖性。
(2)流式细胞术检测结果提示,As2O3影响A-431细胞周期的分布,不同浓度的As2O3作用A-431细胞后S期细胞群增多(P<0.05),存在S期阻滞;并且细胞凋亡数目增多(P<0.05)。
(3)与对照组比较,As2O3能抑制A431细胞survivin基因的表达,该蛋白表达量下降(P<0.05)。三氧化二砷对体外培养的皮肤基底细胞癌细胞株有显著的增殖抑制作用,有诱导表皮细胞癌凋亡作用;并可能与下调凋亡抑制基因Survivin的表达有关。
结论:
1本研究首次应用免疫组化和流式细胞术发现表皮肿瘤皮肤基底细胞癌和SK的发生发展可能与Survivin基因和PTEN基因的异常表达可能有关。联合检测这两种基因有助于判断基底细胞癌的预后和恶性程度的可能性。
2本研究首次应用流式细胞术和免疫组织化学的方法发现皮肤基底细胞癌的发生发展可能与凋亡抑制基因Livin的异常表达可能有关。Livin基因有可能成为皮肤基底细胞癌免疫治疗的靶基因。研究发现Livin和Survivin在皮肤基底细胞癌中的表达呈正相关,在皮肤基底细胞癌发病过程中二者之间可能存在协同作用。而Livin和PTEN在皮肤基底细胞癌中的表达呈负相关。
3本研究首次研究了三氧化二砷对体外培养的皮肤基底细胞癌细胞株增殖和survivin基因表达的影响,结果显示三氧化二砷对皮肤基底细胞癌细胞株有显著的增殖抑制作用,并且有诱导皮肤基底细胞癌细胞凋亡作用和细胞周期阻滞作用;该抑制过程并可能与下调凋亡抑制基因Survivin的表达和影响细胞周期分布有关。
Objectives:Epidermal tumors are ones of the most common malignant or benign tumors in the world. The incidence of basal cell carcinoma (BCC) and seborrheic keratosis (SK) is high in China.They are a great threaten to human health. Therefore, it is extremely important to investigate pathogenesis and search new target and effective drugs for BCC and SK therapy to decrease mortality and prolong life span of patients with epidermal tumors.
Survivin is a novel member of the apoptosis protein family member. Survivin has correlation with tumor development and progress in many human tumors. Its main biological functions include inhibiting cell apoptosis and enhancing cell proliferation. Survivin selectively expresses in most common hunman noeplasms. More and more researchers study it as an ideal target for cancer treatment. Down-regulation of survivin expression can induce cancer cell apoptosis and enhances radiosensitivity in many human cancers. It can be served as marker of prognosis.
PTEN is a dual-specificity lipid phosphase originally identified as a tumor suuressor gene. It frequently mutates and is absent in a number of human cancers, which leads to the weaking or absence of tumor suppressing functions. PTEN plays a critical role in the development and progression of many cancers. PTEN regulates complex signal transduction pathways (such as P13K/AKT pathway, FAK/MAPK cacade, PTEN/P53/MDM2 network), induces G1 cell-cycle arrest and apoptosis, suppresses the vscular formation and inhibits invasion and metastasis of tumors. With further study on the important function of PTEN, an earlier diagnosis, appropriate clinical surveillance, gene-targeted immunotherapy, prognostic evaluation, new drug development and population-oriented first-line prevention of cancers might be possible.
Livin, as a new member of IAPs, plays an important role in anti-cancers. Livin regulates complex signal transduction pathways (such as TAK1/JNK1, et al) in antiapoptotic functions. Many studies have discovered that livin protein and livin mRNA are expressed in many malignant human tumors, but not or down-regulatedly expressed in normal tissues and benign tumors. With further sdudy on the important functions of livin, it can be a gene target in immunotherapy for cancers.
Clinical trials have demonstrated that arsenic trioxide is effective for acute promyelocytic leukemia; it also has the action of induction of apoptosis and inhibition of growth of some solid cancer cells. It can induce differentiation of human nasopharyngeal carcinoma in BALB/C nude mice xenograft model. But the mechanisms are not clearly understood. Based on these facts, studies have been carried out to study its roles in the treatment of solid cancers. Many studies have discovered that arsenic trioxide can be used in many therapies for solid neoplasm.
Therefore, in the present study we examined the expression of survivin, PTEN proteins in the process of carcinogenesis of epidermal tumors and determined the correlation between the levels of these proteins and various clinical and pathological features. Then, we also examined the expression of livin in the process of carcinogenesis of BCC and SK and determined the correlation between the levels of these proteins and various clinical and pathological features;We also analysed the correlation between linvin and survivin, PTEN in BCC and SK. Next, we studied the effects of arsenic trioxide on proliferation, cell cycle distribution, and expression of survivin, PTEN and livin in human epidermal cancer A-431cells.It may deepen our knowledge about epidermal tumors such as basal cell carcinoma and Sk,et al.It might provide theoretical and experimental evidence for utilization of arsenic trioxide in epidermal carcinoma therapy.
Methods:
1 Expression of survivin, PTEN in epidermal tumors and normal skin tissues and the correlation between the levels of these proteins and clinical-pathological features.
Basal cell carcinoma tissues, seborrheic keratosis tissues and normal skin tissues were obtained from resected surgical specimens of epidermal tumors in our dermatology department. There were thirty cases of basal cell carcinoma including 18males and 12 females, who were aged from 45 to 83 years old (averaged 67.40 years old).There were 30 cases of SK including 16 males and 14 females, who were aged from 38 to 70 years old (averaged 54.80 years old).There were 20 cases of normal skin tissues which were from the patients who received surgical treatments in our dermatology department.
All the specimens were verified by pathologic diagnosis. Survivin, PTEN protein expression in normal skin tissues and the lesions of basal cell carcinoma and seborrheic keratosis were examined by immunohistochemistry (IHC). Survivin, PTEN protein expression in normal skin tissues and the lesions of basal cell carcinoma and seborrheic keratosis were also examined by flow cytometry (FCM). Relationship between their expressions and clinical pathological features was analyzed.
2 Expression of livin protein in epidermal tumors and normal skin tissues and the correlation between the levels of this protein and clinical-pathological features and the correlation with survivin and PTEN based on part one study.
In this study, basal cell carcinoma tissues, seborrheic keratosis tissues and normal skin tissues were obtained from resected surgical specimens of epidermal tumors in our dermatology department. All the specimens were verified by pathologic diagnosis. They were the same as in part one study. Livin protein expression in normal skin tissues and the lesions of basal cell carcinoma and seborrheic keratosis were examined by immunohistochemistry (IHC). Livin protein expression in normal skin tissues and the lesions of basal cell carcinoma and seborrheic keratosis were also examined by flow cytometry (FCM). Relationship between its expressions and clinical pathological features was analyzed. Statistical treatment with SPSS was applied to deal with all the experimental data.We also analysed the correlation with survivin and PTEN based on part one study.
3 Effects of arsenic trioxide on cell proliferation, apoptosis, cell cycle distribution and gene expression in human epidermis cancer cell line A-431
Human epidermal carcinoma cells (cell line A431) were conventionally cultured. After treatment with arsenic trioxide in different concentrations, inhibition of cellular growth was determined by measuring MTT dye absorption of living cells in 24,48,72h. We calculated the OD values.Then, apoptosis, cell cycle distribution and survivin expression were assessed by flow cytometry and western Blot methods.
Results:
1 Expression of survivin, PTEN in epidermal tumors and normal skin tissues and the correlation between the levels of these proteins and clinical-pathological features
(1) The protein of survivin was positively expressed in 18 cases of the 30 SK specimens while none was expressed in the 20 normal controls (P<0.05). The protein of PTEN was positively expressed in 17 cases of the 30 SK specimens and in 13 cases of the 20 normal controls (P>0.05).
(2) The protein of survivin was highly expressed in BCC lesions than in SK lesions and in normal controls (P<0.05), while the protein of PTEN was lowly expressed in BCC than in SK lesions and normal controls (P<0.05).
(3) There had been a significant negative correlation between the expressions of survivin and PTEN (r= -0.546, P<0.01) in BCC and SK.
(4) The expressions of survivin and PTEN were related with the patients’age, areas of the lesions and the disease duration (P<0.05), but not related with the patients’genders, sites of lesions and numbers of lesions (P>0.05) in patients with BCC.
2 Expression of livin protein in epidermal tumors and normal skin tissues and the correlation between the levels of this protein and clinical-pathological features and the correlation with survivin and PTEN.
(1) The protein of Livin was highly positively expressed in basal cell carcinoma than in seborrheic keratosis. There was significant difference (P<0.05) and it was also highlier expressed in BCC tissues than in normal controls (P<0.05).
(2) The protein of Livin was highlier expressed in SK lesions than in normal controls, there was significant difference (P<0.05).
(3) From normal skin to seborrheic keratosis and to basal cell carcinoma, the expressions of Livin were getting gradually highlier.
(4) The expressions of livin were related with the patients’age, areas of the lesions and the disease duration (P<0.05), but not related with the patients’gender, sites of lesions and numbers of lesions(P>0.05) in patients with basal cell carcinoma..
(5) There had been a significant positive correlation between the expressions of Livin and Survivin (r= 0.557, P<0.05) in basal cell carcinoma and seborrheic keratosis. There had been a significant positive correlation between the expressions of Livin and PTEN (r=- 0.453, P<0.05) in basal cell carcinoma and seborrheic keratosis.
3 Effects of arsenic trioxide on cell proliferation, apoptosis, cell cycle distribution and gene expression in human epidermis cancer cell A-431
MTT assay showed that with concentrations from 10umol/L to 40umol/L, arsenic trioxide can significantly inhibited the proliferation of A431 cells in a dose- and time-dependent manner (P<0.05). After A-431 cells were dealed with different concentration of arsenic trioxide in 24-72hours, the OD values of the treatment groups decreased to some extent compared with the control group. There were statistically significant differences between them. Survivin expression was significantly downed regulated by arsenic trioxide in A-431 cell line (P<0.05). Arsenic trioxide can inhibit cell proliferation and induce apoptosis in A-431 cells. Arsenic trioxide can also down-regulate the expression of Survivin in A-431 cells. The anti-proliferation effect of arsenic trioxide on human epidermoid carcinoma A-431 maybe is related to down-regulated expression of Survivin gene (P<0.05). Arsenic trioxide can also affect the cell cycle distribution in A-431 cells in our FCM assays. Every group of Arsenic trioxide blocked A-431 cell cycle at S-phase (P<0.05).
Cellular morphology was observed under light microscope: cells shrinkage after treatment, the breakdown was irregular in shapes. Pseudo-foot lenders appeared in some cells at both ends. A-431 cells showed morphological changes.
Conclusions:
(1)Our study found that in the process of carcinogenesis of the basal cell carcinoma, the expression of survivin may play a role in the pathgenesis of BCC and SK while the expression of PTEN may take a part in the protection of BCC and SK. There propably is an interaction between the two genes in BCC and SK. Detecting the two protein levels can provide certain reference value in evaluating the malignant probability and in judging the prognosis of seborrheic keratosis.
(2) It was first found that the abnormally high expressions of Livin protein may play a role in the pathogenesis of seborrheic keratosis and basal cell carcinoma through inhibiting cell apoptosis. From normal skin tissues to seberric kerotosis and to basal cell carcinoma, livin expressions are increasing gradually. Our study suggests that Livin can be a gene target in immunotherapy for epidermal tumors such as BCC and SK. There had been a significant positive correlation between the expressions of Livin and Survivin in BCC and SK.There may be a co-operation between the two genes in basal cell carcinoma and seborrheic keratosis. There had been a significant negtive correlation between the expressions of Livin and PTEN in BCC and SK.
(3) In our study, it was first found that arsenic trioxide can inhibit cell proliferation and induce apoptosis in A-431 cells. Arsenic trioxide can also down-regulate the expression of survivin in A-431 cells. The anti-proliferation effect of arsenic trioxide on human epidermoid carcinoma A-431 maybe is related to down-regulated expression of survivin gene. Arsenic trioxide can also affect the cell cycle distribution in A-431 cells.
引文
1 Ahmed NU, Ueda M, Ichihashi M. P21WAF1/CIP1 expression in nonmelanoma skin tumors [J]. J Cutan Pathol, 1997, 24(4):223-227
2 Li J, Yen C, Liaw D, et al. PTEN,a putative protein tyrosine phosphatase gene mutated in human brain,breast, and prostate cancer[J]. Science, 1997, 275(5308):1943-1947
3 Vazquez F,Matsuoka S,Sellersw WR, et al. Tumor suppressor PTEN acts through dynamic interaction with the plasma membrane[J]. Proc Natl Acad Sci USA, 2006, 103(10):3633-3638
4 Chung JH, Eng C. Nulear-cytoplasmic partitioningof phosphatase and tensin homologue deleded on chromosome 10(PTEN) differentially regulates the cell cycle and apoptosis [J]. Cancer Res. 2005, 65(18):8096-8100
5 Hamada K, Sasaki T, Koni PA, et al. The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis. Genes Dev, 2005, 19(17): 2054-2065
6 Sanchez T, Thangada S, Wu MT, et al. PTEN as an effector in the sigaling of antimigratory G protein-coupled receptor. Proc Natl Acad Sci USA, 2005, 102 (12): 4312-4317
7 Tang Y, Eng C. P53 down-regulates phosphatase and tensin homologue deleted on chromosome 10 protein stability partially through caspase-mediated degradation in cells with proteasome dysfunction. Cancer Rec, 2006, 66(12): 6139-6148
8 Kaper F, Dornhiefer N, Giaccia AJ.Mutations in PI3K/PTEN/TSC2 pathway contribute to mammalian target of rapamycin activity and increased translation under hypoxic conditions. Cancer Rec. 2006, 66(3):1561-1569
9 Vasudevan KM, Gurumurthy S, Rangnekar VM.Suppression of PTEN expression by NF-B prevents apoptosis.Mol Cell Biol, 2004, 24(3):1007-1021
10张伟峰. PTEN基因的研究进展[J].国外医学外科学分册2003,30(5):294-296
11 Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin [J]. Nature, 1998, 396(6711):580-584
12 Suzuki A, Ito T, Kawano H, et al. Survivin initiates procaspas3/p21 complex formation as a result of interaction with CDK4 to resist Fas-mediated cell death [J]. Oncogene, 2000, 19(10):1346-1353
13 Miao GY, Lu QM, Zhang XL. Downregulation of survivin by RNAi inhibits growth of human gastric carcinoma cells.World of Gastroenterol, 2007, 13(8):1170-1174
14 Yamaguchi Y, Shiraki K, Fuke H, et al. Targeting of X-linked inhibitor of apoptosisi protein or survivin by short interfering RNAs sensitizes hepatoma cells to TNF-related apoptosis-inducing ligand-and chemotherapeutic agent-induced cell death. Oncol Rep, 2005, 14(5):1300-1316
15 Nakao K, Hamasaki K, Inchikawa T, et al. Survivin doenregulation by siRNA sensitizes human hepatoma cells to TRALL-induce apoptosis. Oncol REP, 2006, 16(2):389-392
16 Wang Y, Zhu H, Quan L, et al. Downregulation of survivin by RNAi inhibits the growth of esophageal carcinoma cells. Cancer Biol Ther, 2005, 4(9): 974-978
17 Ghadersohi A, Pan D, Fayazi Z, et al. Prostate-derived Ets transcription factor (PDEF) downregulates surviving expression and inhibits breast cancer cell growth in vitro and xenofraft tumor formation in vivo. Breast Cancer Res Treat, 2007, 102(1):19-30
18张培荣,郑锦花,王艳萍,等. Survivin和PTEN蛋白在宫颈鳞状细胞癌中的表达及临床意义[J].临床肿瘤学杂志. 2007, 12(4):271-274.
19彭程,施岩,路麒,张莉. P16、P21WAF1/CIP1, PCNA和Cyclin E在脂溢性角化病中的表达及其意义[J].中国麻风皮肤病杂志. 2007, 23(8):658-660
20 Hussein MR, AL-Badaiwy ZH, Guirgui MN. Analysis of p53 and bcl-2protein expression in the non-tumorigenic, pretumorigenic, and tumorigenic kerotinocytic hyperproliferative lesions [J]. J cutan Pathol, 2004, 31(10): 643-651
21 Stephenson TJ, Royds J, Silcocks PB, er al.Mutant P53 oncogene expression in keraacanthoma and squamous cell carcinoma. Br J Dermatol, 1992, 127: 566-561
22 Mcgregor JM, Yu CCW, Dublin EA, et al. Aberrant expression of P53 protein tumor-suppressor protein in non-melanoma skin cancer. Br J Dermatol, 1992, 127: 463-467
23 Rady P, Scinicariello F, Wagner RF, et al. P53 mutations in basal cell carcinomas. Cancer Res, 1992, 52:3804-3809
24 Shea CR, Menutt NS, Volkenandt M, et al. Over expression of P53 protein in basal cell carcinoma of human skin. Am J Dermatopathol, 1992, 141: 25-31
1张勇,彤涛,李存孝,等.人骨肉瘤组织中Livin的表达[J].现代肿瘤医学. 2006, 14(5):605-607
2 Ahmed NU, Ueda M, Ichihashi M. P21WAF1/CIP1 expression in nonmelanoma skin tumors [J]. J Cutan Pathol, 1997, 24(4): 223-227
3 Kasof GM, Gomes BC. Livin, a novel inhibitor of apoptosis protein family member [J]. J Biol Chem, 2001, 276(5): 3238-3246
4 Boaz Nachmias, Yaqoub Ashhab, Vered Bucholtz, et al. Caspase-mediated cleavage converts livin from an antipoptotic to an apoptotic factor: implications for drug-resistant melanoma [J]. Cancer Res, 2003, 63(19): 6340-6349
5 Sanna MG, Da Silva Correia J, Ducrey O et al. IAP suppression of apoptosis involves distinct mechanism: theTAK1/JNK1 signaling cascade and caspase inhibition [J]. Mol Cell Biol, 2002, 22(6): 1754-1766
6 Vucic D, Deshayes K, Ackerly H, et al. SMAC negatively regulates the antiapoptotic activity of melanoma inhibitor of apoptosis (MLIAP) [J].J Biol Chem, 2002,277(14):12275-12279
7 Vazquez F, Matsuoka S, Sellersw WR, et al. Tumor suppressor PTEN acts through dynamic interaction with the plasma membrane [J]. Proc Natl Acad Sci USA, 2006, 103(10): 3633-3638
8 Vucic D, Stennicke HR,Pisabarro MT,et al.ML IAP,a novel inhibitor of apoptosis that is preferentially expressed in human melanomas [J]. Curr Biol, 2000, 10(21): 1359-1366.
9 Yagihashi A, Asanuma K, Tsuji N, et al. Detection of anti livin antibody in gastrointestinal cancer patients [J]. Clin Chem, 2003; 49(7): 1206-1208
10 Schmollinger JC, Vonderheide RH, Hoar KM, et al. Melanoma inhibitor of apoptosis protein (ML IAP) is a target for immune mediated tumor destruction [J]. Proc Natl Acad Sci USA, 2003; 100(6): 3398-3403
11 Gazzaniga P, Gradilone A, Giulian L, et al. Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progressions of superficial bladder cancer [J]. Ann Oncol, 2003; 14(1): 85-90
12李日恒,宋燕,张海山,等.新发现的Livin基因在结肠癌组织中的mRNA表达及其临床意义[J].中国实验诊断学杂志,2006;10(12):6041-6043
13 Xiang Y, Yao H, Wang S, et al. Prognostic value of Survivin and Livin in nasopharyngeal carcinoma [J]. Larngoscope, 2006, 116(1): 126-129.
14 Tanabe H, Yagihashi A, Tsuji N, et al. Expression of surviving mRNA andlivin mRNA in non-small-cell lung cancer [J]. Lung Cancer, 2004, 46(3): 299-304
15 Wagener Ncrnkovi-Mertens I.Expression of inhibitor of apoptosis protein livin in renal carcinoma and non-tumorous adult kidney [J]. British Jounal of Cancer, 2007, 97:1271-1276
16 Hariu H, Hirohashi Y, Torigoe T, et al. Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis family, livin/ML-IAP in lung cancer [J]. Clin Cancer Ras, 2005, 11(3): 1000
17祝兴旺,张明明,宋永胜.凋亡抑制蛋白livin在膀胱移行细胞癌中表达及临床意义.中华实用诊断与治疗杂志, 2009, 23(2):121-123
18 Crnkovic-Mertens 1, Hoppe-Seyler F, Butz K.Introduction of apoptosis in tumor cells by siRNA-mediated silencing of the livin/ML-IAP/KIAP gene [J]. Oncogene, 2003, 22(51): 8330-8336
19 Nachmias B, Mizrahi S.Manipulation of NK cytotoxicity by the IPA Family member livin [J]. Eur J Immunol, 2007, 37(12): 3467-3476
20 Jaewon C, Yu K.Expression of livin, an antiapoptotic protein, is an independent favorable prognostic factor in childhood acute lymphoblastic leukemia [J]. Blood, 2007, 109:471-477
1 Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med, 1998, 339:1341-1348
2 Du CW, Li Dr, Wang ZG, et al. Arsenic trioxide induces differentiation of human nasopharyngeal carcinoma in BALB/C nude mice xenograft model. Ai Zheng, 2003, 22(1): 21-25
3 Baj G, Arnulfo A, Deaglio S, et al. Arsenic trioxide and breast cancer:analysis of the apoptic, differentiative and immunomodulatory effects. Breast Cancer Res Treat, 2002, 73(1): 61-63
4 Ling YH, Jiang JD, Holland JF, et al. Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines. Mol Pharmacol, 2002, 62(3): 529-538
5 Haga N, Fujita N, Tsuruo T, Involvement of microhondrial aggregation in Arsenic trioxide-induced apoptosis in human glioblastoma cells. Cancer Sci, 2005, 96(11): 825-833
6 O’Relly MA, Staversky RJ, Watkins RH, ET al.p53-independent induction of GADD45 andGADD153 in mouse lungs exposed to hyperoxia. Am J Physicol Lung Cell Mol Physiol, 2000, 278(3): L552-L559
7 Yao H, Wu QL, Wang HM, et al. Effects of Arsenic trioxide on cell apoptosis and hTERT mRNA of human tongue cancer cells. Hua Xi Kou Qiang Yi Xue Za Zhi, 2005, 23(5): 442-444
8王南瑶,刘琳,邱少敏,等.三氧化二砷对人结肠癌裸鼠抑制瘤端粒酶活性及其催化亚单位表达活性的影响.东南大学学报:医学版, 2005, 24(3):168-170
9方成,陈振光,喻爱喜,等.三氧化二砷诱导骨肉瘤细胞凋亡的研究.中华骨科杂志, 2003, 23: 345-348
10刘向东,张伟,吴文娟,等.亚砷酸动脉灌注在骨肉瘤新化疗中的作用.河北医药, 2007, 29(10):1064-1065
11毕新岭,刘雅妍,顾军,等.三氧化二砷对体外培养的HaCat细胞基因表达的影响.中华皮肤科杂志, 2007, 40(11):705-706
12毕新岭,顾军,陈志强,等.亚砷酸对角质形成细胞增殖及凋亡的影响.中华皮肤科杂志, 2002, 35(6):457-459
13陈昌杰,陈正徐,章尧.三氧化二砷对HL-60细胞凋亡及Survivin和Caspase-3表达的影响.临床肿瘤学杂志, 2007, 12(5):346-349
14李航宇,鞠培新,钟鑫平,等.三氧化二砷诱导人肝癌细胞株HepG2凋亡的机制研究.中国肿瘤临床, 2008, 35(4):210-213
15孙华君,姜立新,董国生,等.三氧化二砷抑制人结肠癌裸鼠肝转移的药效动力学.肿瘤防治研究, 2008, 35(12): 0842-0844
16 Zhang YL, Wei HL, Sun LJ. Impact of As2O3 on Bcl-2, survivin and Reactive Oxygen Species (ROS) expression during the process of induced apoptosis in multidrug-resistent human leukemia K562/ADM cells [J]. China journal of oncology, 2008, 17(6): 495-499
17 Cheng YH, Louis W, Tsui C.Mitogen-activated protein kinasea mediate arsenic-induced doen-regulation of surviving in human lung adenocarcinoma cells [J]. Arch Toxicol, 2006, 80(2): 310-318
18 Yih LH, Peck K, Lee TC.Changes in gene expression profiles of human fibroblasts in response to sodium arsenite treatment. Carcinogenesis, 2002, 23 (5): 867-876
19 Akao Y, Yamada H, Nakagawa Y.Arsenic-induced apoptosis in malignant cells in vitro. Lurk Lymphoma, 2000, 37:53-63
20 Park WH, Seol JG, Kim ES, et al. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cylin-dependent kinase inhibitor, p21, and apoptosis. Cancer Rec, 2000, 60:3065-3071
1 Weedon DSkinPathology [M]. Sydney: Churchill Livingstone, 2002:767
2 Rahhbari H, Mehregan AH.Basal cell epithelioma in usual and unusal site [J].J Cutan pathol, 1979, 6(5):425-431
3 Maccormack CJ, Kelly JW, Dorevitch Ap.Dfference in age and body site distribution of the histologic subtype’s os the basal cell carcinoma. A possible indicator of differing causes [J]. Arch Dermatol, 1997, 166(5): 593-596
4 Hendrix JD, Parllet HL.Micronodular basal carcinoma [J]. Arch Dermatol, 1996, 132(3): 295-298
5 Salache SJ, Amonette RA.Morphesform basal cell epitheliomas. A study of subclinical extentions in a series of 51 cases [J]. J Dermatol Surg Oncol, 1981, 7(4): 387-394
6 Rossen K, Haerslev T, Hou-Jensen K, et al. Metallothionein expression inbasaloid proliferations overlying dermatofibromas and in basal cell carcinoma [J]. Br J Dermatol, 1997, 136(1): 30-34
7 Hartschuh W, Schulz T.Merkel cell hyperplasia in chronic radiationdamaged skin: its possible relationship to fibroepithelioma of Pinkus [J]. Cutan Pathol, 1997,24(5): 477-483
8 Martin RC 2nd, Edwards Mj, Cawte TG, et al. Basosquamous carcinoma: analysis of prognistic factors influencing reccurrence [J]. Cancer, 2000, 88(6): 1365-1369
9 Beer TW, Shepherd P, Theak JM.Ber EP4 and epithelial membrane antigen aid distinction of basal cell, squamous cell and basosqumous carcinoma of the skin [J]. Histopathology, 2000, 37(3): 218-223
10 Lao LM, Kumakiri M, Kiyohara T, et al. Sub-populations of melanocytes in pigmented basal cell carcinoma: a quantitative, ultrastructural investigation [J]. L Cutan Pathol, 2001, 28(1): 34-43
11 Giles GG, Marke R, Foley P, et al. Incidence of non-melanocytic skin cancer treated in Australia.Br Med J (clin Res Ed). 1998, 296:13-17
12 Ortonne JP.From actinic keratosis to squmaous cell carcinoma. Br J Dermatol.2002, 146suppl16: 20-23
13 Billeret-Lebranchu V, Martin de lasalle V, et al. Granular cell tumor and congenital epulis. Hischemical and immunohischemical of 58 cases. Arch Anat Cytol Pathol.1999, 47:31-37
14 Motley R, Kersey P, Lawrence C.Multiprofessional guidelines for the management of the patients with primary cutaneous squamous cell carcinoma. Br J Dermatol.2002, 146:18-25
15 Nguyen P, Vin-christian K, Ming ME, et al. Aggressive squamous cell carcinima in persons infected with the human immunodeficiency. Arch Dermatol.2002, 138:758-763
16 Turner RJ Leonard N, Malcolm AJ, et al. A retrospective study of outcome of Mohs’micrographic surgery for cutaneous squmaous cell carcinoma-using formalin fixed sections. Br. J Dermatol. 2000, 142: 752-757
17 Kao GF.Carcinoma arising in Bowen’s desease. Arch Dermatol.1986, 122:1124-1126
18 Khanna M, Fortier-Riberdy G, Smoller B, et al. Reportin tumor thickness for cutaneous squamous cell carcinoma. J Cutan Pathol.2002, 29:321-323
19 Rowe DE, Carroll RJ, Day CLJr, et al. Prognostic factors for local recurrence, metastasis, and survival rates in squmaous cell carcinoma of the skin, ear and lip. Implications for treatment modality selections. J Am Acad Dermatol.1992, 26:976-990
20藤蔚,史同新,曲才杰.PTEN和Survivin在鳞状细胞癌中的表达[J].中国麻风皮肤病杂志,2005, 21(6):438-440
21 Chiodino C, Cesinaro AM, and Ottani D, et al. Communication: expression of the novel inhibitor of apoptosis survivin in normal and neoplastic skin. J Invest Dermatal 1999, 113:415-418
22 Lo Muzio L, Staibano S, Pannoe G, et al. Expression of the apoptosis inhibitor Survivin in the aggressive squamous cell carcinoma. Exp Mol Pathol 2001, 70:249-254
23刘振祥,崔建. P16, P21和cyclinD1mRNA在皮肤鳞状细胞癌中的表达.北京医科大学学报, 1998, 10(5):471-472
24 Shea CR, Menutt NS, Volkeandt M, et al. Over expression of p53 protein in basal cell carcinoma of human skin.[J].Am J Dermatolpathol, 1992, 141:25
25 Rady P, Scinicariello F, Wagner RF, et al. P53 mutations in basal cell carcinomas. Cancer Res, 1992, 52:3804
26 Stephen TJ, Rords J, Silcocks PB, et al. Mutant p53 oncogene expression in keratoacanthoma and squamous cell carcinoma [J]. Br J Dermatol, 1992, 127:566
27 Mcgregor JM, YU CCw, Dublin EA, et al. Aberrant expression of p53 protein tumor-suppressor protein in non-melonoma skin cancer [J]. Br J Dermatol, 1992; 127:463-467
28李慧忠,樊翌明,李顺凡,等.CD44v6和PCNA在皮肤鳞状细胞癌中的表达及其临床意义[J].中国麻风皮肤病杂志, 2004, 20(1):01-03
29田重伟,皮肤鳞状细胞癌中FHIT蛋白的检测及临床意义[J].中国皮肤性病学杂志, 2005, 19(2):68-71
30 Pierccall WE, Goldberg LH, Tainsky MA, et al. Ras gene mutation and amplication in human non-melonoma skin cancers. Mol Carcinog, 1991, 4:196-210
31 Ananthaswamy HN, Price JE, Goldberg LH, et al. Detection and identification of activated oncogenes in human skin cancers occurring on sun-exposed body sites [J]. Cancer Res, 1988, 48:33-41
32 Gart SJ, Bms FJ, Ashkenazi-Kimmel t, et al. Amplification of the c-myc oncogene during progression of radition-induced rat skin tumors [J]. Cancer Res, 1990, 50:3073-3076
33 Zhu WY, Leonardi C, Penney NS.Detection of human papillomavirus DNA in seborheic keratosis by polymerase chain reaction. J Dermatol Sci 1992, 4:166-171
34 Weinstock MA.Epidemiologic investigation of nonmelanoma skin cancer mortality: the Rhode Island Follow-Back study. J invests Dermatol. 1994, 102:6s-9s
35 Lund KA. How often does squamous cell carcinoma of the skin metastasize? Arch Dermatol. 1965, 92:635-637
36 Moler R, Reymann F, Hou-Jensen K, et al. Metastases in dermatological patients with squamous cell carcinoma. Arch Dermatol. 1979, 115:703-703
37 Alam M, Ratner F.Cutaneous squamous cell carcinoma. N Engl J Med. 2001, 344:975-983
38 Dinehart SM. The treatment for actinic keratosis. J Am Acad Dermatol. 2000,42:25-28
39 Rowe DE, Carroll JR, Day Cljr, et al. Prognostic factors of local recurrence, metastasis, and survival rates in squamous cell carcinoma of thr skin, ear, and lip Implication for treatment modality selection. J Am Acad Dermatol.1992, 26:976-990
40 Marcil I, Stern RS.Risk of developing a subsequent nonmelanoma skinscancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol. 2000, 136:1524-1530
41 Miller SJ.The National Comprehensive Cancer Network (NCCN) guides of care for nonmalenoma skin cancers. Dermatol Surg, 2000, 26:289-292
42 Rowe DE, Caroll RJ, DayCLJr, et al. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implication for patient follow-up. J Dermatol Surg Oncol.1989, 15:315-328
43 Lo JS, Snow SN, Reizner GT, et al. Matastatic basal cell carcinoma: report of twelve cases with review of the literature. J Am Acad Dermatol. 1991, 24:725-719
44 Karagas MR.Occurrence of cutaneous basal cell and squamous cell among those with a prior history of skin cancer. The skin carcinoma cancer prevention study group. J Invest Dermatol. 1994, 102: 10s-13s
45 Lindelof B, Sigurgeirsson B, Wall-berg P, et al. Occurrence of other malignancies in 1973 patients with basal cell carcinoma. J Am Acad Dermatol.1991, 25:245-248
1 David Gill, Abe Dorevitch, Robin Marks.The prevalence of seborrheic keratosis in people aged 15 to 30 years, is the term senile keratosis redundant? Arch Dermatol 2000, 136:759-762
2高文天,李春英,黄慧.脂溢性角化病231例临床和病理分析.临床皮肤科杂志2002, 31:279-281
3 Zhu WY, Leonardi C, Penney NS. Detection of human papillomavirus DNA in senile keratosis by polymerase chain reaction. J Dermatol Sci 1992, 4:166-171
4 Yeatman JM, Killenny M, Marks R.The prevalence of seborrheic keratosis in an Australian population: dose exposure to sunlight plays a part in their freguency? British J of Dermatol 1997, 137:411-414
5常建民,吴意平,杨敏.老年性脂溢性角化患者血脂、脂蛋白、载脂蛋白的分析.临床皮肤科杂志2002, 31: 85-86
6 Sloan JB, Jaworsky C.Clinical misdiognosisi of squamous cell carcinoma in situ as seborrheic keratosis. A prospective study. J Dermatol Surg Oncol 1993, 19:413-416
7 Rao BK, Fraaman RC, Paulos EG, et al. The relationship between basal cell epithelioma and seborrheic kerotosis. J Dermatol Surg oncol1994: 20:761-764
8 Urano Y, Oura H, Sakaki A, et al.immunohistological analysis of P53 expression in human skin tumors. J Dermatol Sci.1993, 5:212-213
9 Nakagawa K, Ramamura Kmaeda S, et al. Bcl-2 expression of epidermal keratinocytic disease. Cancer 1994, 74:1720-1724
10 Tanikawa E, Mori D, Harchisuka H, et al. Expression of ras proto-oncogene related protein P21 in normal human skin and cutaneous tumors. Acta Histochem.1992, 93:282-289
11王晓彦,萨娜,王泽民,等.鳞癌和脂溢性角化病DNA倍体图像定量分析.中国皮肤性病学杂志2000, 14: 88-89
12 Nakamura H, Hirotus S.Adachi S, et al. Clonal nature of seborrheickeratosis demonstrated using the polymorphism of the human androgen receptor locusas a marker. J invests Dermatol 2001, 116:506-5510
13 Grob JJ, Rava MC, Gouvernet J, et al. The relation between seborrheic keratosis and malignant solid tumors. A case-control study. Acta Derm Venereol 1991, 71:166-169
14 Nakamura H, Hirota S, Adachi S, et al. Clonal nature of seborrheic keratosis demonstrated by using the polymorphism of the human androgen receptor locus as a marker. J invests Dermatol.2001, 116:506-510
15 Pesce D, Scalora S, Apoptosis in the area of squamous differentiation irritated seborrheic keratosis. J cuta Pathol 2000, 27: 121-123
16李澄,周红,樊小妹,等. EGF、EGFr在脂溢性角化病组织中的表达.临床皮肤科杂志2001, 30:225-226
17彭程,施岩,路麒,张莉. P16、P21WAF1/CIP1、PCNA和Cyclin E在脂溢性角化病中的表达及其意义[J].中国麻风皮肤病杂志.2007, 23(8):658-660
18李颖,何威,林自华,等.脂溢性角化病皮损的表皮中TGF-?受体表达下调[J].第三军医大学学报, 2006, 28(3):239-242
19杨扬,何威,何云志,等.脂溢性角化病、基底细胞癌和鳞状细胞癌中几种Smad蛋白表达的检测[J].临床皮肤科杂志, 2007, 36(7):423-425
20 LEE SC, LEE JB, Seo JJ, et al. Expression of trichohyalin in dermatological disorder. A comparative study with involucrin and filaggrin immunohisto chemical staining. Acta Derm Venereol1999, 79:97
21 Sumitono S, Kumasa S, Iwai Y, et al. Involucrin expression in epithelial tumor of oral ang pharyngeal mucosa and skin. Ora surg oral Med Oral Pathol, 1986, 62:63
22 Fujisawa H, Naito Y, Muraki R, et al. Diferentiation disorders of keratinocytes in seborrheic keratosis (acantholic type). J Dermatol, 1991, 18:635-638
23 Luzi P, Miracco C, Del Vecchio MT.Stereological study of desmosomes in basal cellcarcinoma and seborrheic keratosis. J Submicrosc Cytol, 1987, 19:337-343
24 Kwon OS, Hwang EJ, and Bae JH, et al. seborrheic keratosis in the Korean males: causative role of sunlight. Photodermatol photoimmuol photomed, 2003, 19(2): 73-80
25 Manaka L, Kadono S, Kawashima M, et al. The mechanism of hyperpigmentation in seborrheic keratosis involves the high expression of endothelin-converting enzyme-1 alpha and TNF-alpha, which stimulate secretionof endothelin1. Br J Dermatol, 2001, 145:895-903
26 Wu juan,Sheng wan-xiang.Expression of ET-1,ECE-1 and YNF-αin the lesions of seborrheic keratosis.China J Dermatol, 2009, 42(2): 143
27 Asagami C, Muto M, Hirota T, et al. Anti-tumor effects of 1,25-dihydroxyvitaminD3 [1,25(OH)2D3] in seborrheic keratosis. J Investing Dermatol Symp Proc.1996, 1:94-96
28 Benodi D, Pezzarossa E, Alinovi A, et al. Retinoic acid and 5-Fu mixture in the topical treatment of several skin deseases. Ateneo Parmense Acta Biomed. 1980: 51:182-192
29 Feuerman EJ, Katzenelson V, Halevy S.olcoderm in the treatment of solar and seborrheic keratosis. Dermatologica, 1984:168Suppl 1:33-35
30 Broekaert D, Leigh IM, Lane EB, et al. An immunohischemical and histochemical study of cytokeratin, involucrin and transglutaminase in seborrhoeic keratosis. Arch Dermatol Res.1993, 285:482-490
2 Li J, Yen C, Liaw D, et al. PTEN,a putative protein tyrosine phosphatase gene mutated in human brain,breast, and prostate cancer[J]. Science, 1997, 275(5308):1943-1947
3 Vazquez F,Matsuoka S,Sellersw WR, et al. Tumor suppressor PTEN acts through dynamic interaction with the plasma membrane[J]. Proc Natl Acad Sci USA, 2006, 103(10):3633-3638
4 Chung JH, Eng C. Nulear-cytoplasmic partitioningof phosphatase and tensin homologue deleded on chromosome 10(PTEN) differentially regulates the cell cycle and apoptosis [J]. Cancer Res. 2005, 65(18):8096-8100
5 Hamada K, Sasaki T, Koni PA, et al. The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis. Genes Dev, 2005, 19(17): 2054-2065
6 Sanchez T, Thangada S, Wu MT, et al. PTEN as an effector in the sigaling of antimigratory G protein-coupled receptor. Proc Natl Acad Sci USA, 2005, 102 (12): 4312-4317
7 Tang Y, Eng C. P53 down-regulates phosphatase and tensin homologue deleted on chromosome 10 protein stability partially through caspase-mediated degradation in cells with proteasome dysfunction. Cancer Rec, 2006, 66(12): 6139-6148
8 Kaper F, Dornhiefer N, Giaccia AJ.Mutations in PI3K/PTEN/TSC2 pathway contribute to mammalian target of rapamycin activity and increased translation under hypoxic conditions. Cancer Rec. 2006, 66(3):1561-1569
9 Vasudevan KM, Gurumurthy S, Rangnekar VM.Suppression of PTEN expression by NF-B prevents apoptosis.Mol Cell Biol, 2004, 24(3):1007-1021
10张伟峰. PTEN基因的研究进展[J].国外医学外科学分册2003,30(5):294-296
11 Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin [J]. Nature, 1998, 396(6711):580-584
12 Suzuki A, Ito T, Kawano H, et al. Survivin initiates procaspas3/p21 complex formation as a result of interaction with CDK4 to resist Fas-mediated cell death [J]. Oncogene, 2000, 19(10):1346-1353
13 Miao GY, Lu QM, Zhang XL. Downregulation of survivin by RNAi inhibits growth of human gastric carcinoma cells.World of Gastroenterol, 2007, 13(8):1170-1174
14 Yamaguchi Y, Shiraki K, Fuke H, et al. Targeting of X-linked inhibitor of apoptosisi protein or survivin by short interfering RNAs sensitizes hepatoma cells to TNF-related apoptosis-inducing ligand-and chemotherapeutic agent-induced cell death. Oncol Rep, 2005, 14(5):1300-1316
15 Nakao K, Hamasaki K, Inchikawa T, et al. Survivin doenregulation by siRNA sensitizes human hepatoma cells to TRALL-induce apoptosis. Oncol REP, 2006, 16(2):389-392
16 Wang Y, Zhu H, Quan L, et al. Downregulation of survivin by RNAi inhibits the growth of esophageal carcinoma cells. Cancer Biol Ther, 2005, 4(9): 974-978
17 Ghadersohi A, Pan D, Fayazi Z, et al. Prostate-derived Ets transcription factor (PDEF) downregulates surviving expression and inhibits breast cancer cell growth in vitro and xenofraft tumor formation in vivo. Breast Cancer Res Treat, 2007, 102(1):19-30
18张培荣,郑锦花,王艳萍,等. Survivin和PTEN蛋白在宫颈鳞状细胞癌中的表达及临床意义[J].临床肿瘤学杂志. 2007, 12(4):271-274.
19彭程,施岩,路麒,张莉. P16、P21WAF1/CIP1, PCNA和Cyclin E在脂溢性角化病中的表达及其意义[J].中国麻风皮肤病杂志. 2007, 23(8):658-660
20 Hussein MR, AL-Badaiwy ZH, Guirgui MN. Analysis of p53 and bcl-2protein expression in the non-tumorigenic, pretumorigenic, and tumorigenic kerotinocytic hyperproliferative lesions [J]. J cutan Pathol, 2004, 31(10): 643-651
21 Stephenson TJ, Royds J, Silcocks PB, er al.Mutant P53 oncogene expression in keraacanthoma and squamous cell carcinoma. Br J Dermatol, 1992, 127: 566-561
22 Mcgregor JM, Yu CCW, Dublin EA, et al. Aberrant expression of P53 protein tumor-suppressor protein in non-melanoma skin cancer. Br J Dermatol, 1992, 127: 463-467
23 Rady P, Scinicariello F, Wagner RF, et al. P53 mutations in basal cell carcinomas. Cancer Res, 1992, 52:3804-3809
24 Shea CR, Menutt NS, Volkenandt M, et al. Over expression of P53 protein in basal cell carcinoma of human skin. Am J Dermatopathol, 1992, 141: 25-31
1张勇,彤涛,李存孝,等.人骨肉瘤组织中Livin的表达[J].现代肿瘤医学. 2006, 14(5):605-607
2 Ahmed NU, Ueda M, Ichihashi M. P21WAF1/CIP1 expression in nonmelanoma skin tumors [J]. J Cutan Pathol, 1997, 24(4): 223-227
3 Kasof GM, Gomes BC. Livin, a novel inhibitor of apoptosis protein family member [J]. J Biol Chem, 2001, 276(5): 3238-3246
4 Boaz Nachmias, Yaqoub Ashhab, Vered Bucholtz, et al. Caspase-mediated cleavage converts livin from an antipoptotic to an apoptotic factor: implications for drug-resistant melanoma [J]. Cancer Res, 2003, 63(19): 6340-6349
5 Sanna MG, Da Silva Correia J, Ducrey O et al. IAP suppression of apoptosis involves distinct mechanism: theTAK1/JNK1 signaling cascade and caspase inhibition [J]. Mol Cell Biol, 2002, 22(6): 1754-1766
6 Vucic D, Deshayes K, Ackerly H, et al. SMAC negatively regulates the antiapoptotic activity of melanoma inhibitor of apoptosis (MLIAP) [J].J Biol Chem, 2002,277(14):12275-12279
7 Vazquez F, Matsuoka S, Sellersw WR, et al. Tumor suppressor PTEN acts through dynamic interaction with the plasma membrane [J]. Proc Natl Acad Sci USA, 2006, 103(10): 3633-3638
8 Vucic D, Stennicke HR,Pisabarro MT,et al.ML IAP,a novel inhibitor of apoptosis that is preferentially expressed in human melanomas [J]. Curr Biol, 2000, 10(21): 1359-1366.
9 Yagihashi A, Asanuma K, Tsuji N, et al. Detection of anti livin antibody in gastrointestinal cancer patients [J]. Clin Chem, 2003; 49(7): 1206-1208
10 Schmollinger JC, Vonderheide RH, Hoar KM, et al. Melanoma inhibitor of apoptosis protein (ML IAP) is a target for immune mediated tumor destruction [J]. Proc Natl Acad Sci USA, 2003; 100(6): 3398-3403
11 Gazzaniga P, Gradilone A, Giulian L, et al. Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progressions of superficial bladder cancer [J]. Ann Oncol, 2003; 14(1): 85-90
12李日恒,宋燕,张海山,等.新发现的Livin基因在结肠癌组织中的mRNA表达及其临床意义[J].中国实验诊断学杂志,2006;10(12):6041-6043
13 Xiang Y, Yao H, Wang S, et al. Prognostic value of Survivin and Livin in nasopharyngeal carcinoma [J]. Larngoscope, 2006, 116(1): 126-129.
14 Tanabe H, Yagihashi A, Tsuji N, et al. Expression of surviving mRNA andlivin mRNA in non-small-cell lung cancer [J]. Lung Cancer, 2004, 46(3): 299-304
15 Wagener Ncrnkovi-Mertens I.Expression of inhibitor of apoptosis protein livin in renal carcinoma and non-tumorous adult kidney [J]. British Jounal of Cancer, 2007, 97:1271-1276
16 Hariu H, Hirohashi Y, Torigoe T, et al. Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis family, livin/ML-IAP in lung cancer [J]. Clin Cancer Ras, 2005, 11(3): 1000
17祝兴旺,张明明,宋永胜.凋亡抑制蛋白livin在膀胱移行细胞癌中表达及临床意义.中华实用诊断与治疗杂志, 2009, 23(2):121-123
18 Crnkovic-Mertens 1, Hoppe-Seyler F, Butz K.Introduction of apoptosis in tumor cells by siRNA-mediated silencing of the livin/ML-IAP/KIAP gene [J]. Oncogene, 2003, 22(51): 8330-8336
19 Nachmias B, Mizrahi S.Manipulation of NK cytotoxicity by the IPA Family member livin [J]. Eur J Immunol, 2007, 37(12): 3467-3476
20 Jaewon C, Yu K.Expression of livin, an antiapoptotic protein, is an independent favorable prognostic factor in childhood acute lymphoblastic leukemia [J]. Blood, 2007, 109:471-477
1 Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med, 1998, 339:1341-1348
2 Du CW, Li Dr, Wang ZG, et al. Arsenic trioxide induces differentiation of human nasopharyngeal carcinoma in BALB/C nude mice xenograft model. Ai Zheng, 2003, 22(1): 21-25
3 Baj G, Arnulfo A, Deaglio S, et al. Arsenic trioxide and breast cancer:analysis of the apoptic, differentiative and immunomodulatory effects. Breast Cancer Res Treat, 2002, 73(1): 61-63
4 Ling YH, Jiang JD, Holland JF, et al. Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines. Mol Pharmacol, 2002, 62(3): 529-538
5 Haga N, Fujita N, Tsuruo T, Involvement of microhondrial aggregation in Arsenic trioxide-induced apoptosis in human glioblastoma cells. Cancer Sci, 2005, 96(11): 825-833
6 O’Relly MA, Staversky RJ, Watkins RH, ET al.p53-independent induction of GADD45 andGADD153 in mouse lungs exposed to hyperoxia. Am J Physicol Lung Cell Mol Physiol, 2000, 278(3): L552-L559
7 Yao H, Wu QL, Wang HM, et al. Effects of Arsenic trioxide on cell apoptosis and hTERT mRNA of human tongue cancer cells. Hua Xi Kou Qiang Yi Xue Za Zhi, 2005, 23(5): 442-444
8王南瑶,刘琳,邱少敏,等.三氧化二砷对人结肠癌裸鼠抑制瘤端粒酶活性及其催化亚单位表达活性的影响.东南大学学报:医学版, 2005, 24(3):168-170
9方成,陈振光,喻爱喜,等.三氧化二砷诱导骨肉瘤细胞凋亡的研究.中华骨科杂志, 2003, 23: 345-348
10刘向东,张伟,吴文娟,等.亚砷酸动脉灌注在骨肉瘤新化疗中的作用.河北医药, 2007, 29(10):1064-1065
11毕新岭,刘雅妍,顾军,等.三氧化二砷对体外培养的HaCat细胞基因表达的影响.中华皮肤科杂志, 2007, 40(11):705-706
12毕新岭,顾军,陈志强,等.亚砷酸对角质形成细胞增殖及凋亡的影响.中华皮肤科杂志, 2002, 35(6):457-459
13陈昌杰,陈正徐,章尧.三氧化二砷对HL-60细胞凋亡及Survivin和Caspase-3表达的影响.临床肿瘤学杂志, 2007, 12(5):346-349
14李航宇,鞠培新,钟鑫平,等.三氧化二砷诱导人肝癌细胞株HepG2凋亡的机制研究.中国肿瘤临床, 2008, 35(4):210-213
15孙华君,姜立新,董国生,等.三氧化二砷抑制人结肠癌裸鼠肝转移的药效动力学.肿瘤防治研究, 2008, 35(12): 0842-0844
16 Zhang YL, Wei HL, Sun LJ. Impact of As2O3 on Bcl-2, survivin and Reactive Oxygen Species (ROS) expression during the process of induced apoptosis in multidrug-resistent human leukemia K562/ADM cells [J]. China journal of oncology, 2008, 17(6): 495-499
17 Cheng YH, Louis W, Tsui C.Mitogen-activated protein kinasea mediate arsenic-induced doen-regulation of surviving in human lung adenocarcinoma cells [J]. Arch Toxicol, 2006, 80(2): 310-318
18 Yih LH, Peck K, Lee TC.Changes in gene expression profiles of human fibroblasts in response to sodium arsenite treatment. Carcinogenesis, 2002, 23 (5): 867-876
19 Akao Y, Yamada H, Nakagawa Y.Arsenic-induced apoptosis in malignant cells in vitro. Lurk Lymphoma, 2000, 37:53-63
20 Park WH, Seol JG, Kim ES, et al. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cylin-dependent kinase inhibitor, p21, and apoptosis. Cancer Rec, 2000, 60:3065-3071
1 Weedon DSkinPathology [M]. Sydney: Churchill Livingstone, 2002:767
2 Rahhbari H, Mehregan AH.Basal cell epithelioma in usual and unusal site [J].J Cutan pathol, 1979, 6(5):425-431
3 Maccormack CJ, Kelly JW, Dorevitch Ap.Dfference in age and body site distribution of the histologic subtype’s os the basal cell carcinoma. A possible indicator of differing causes [J]. Arch Dermatol, 1997, 166(5): 593-596
4 Hendrix JD, Parllet HL.Micronodular basal carcinoma [J]. Arch Dermatol, 1996, 132(3): 295-298
5 Salache SJ, Amonette RA.Morphesform basal cell epitheliomas. A study of subclinical extentions in a series of 51 cases [J]. J Dermatol Surg Oncol, 1981, 7(4): 387-394
6 Rossen K, Haerslev T, Hou-Jensen K, et al. Metallothionein expression inbasaloid proliferations overlying dermatofibromas and in basal cell carcinoma [J]. Br J Dermatol, 1997, 136(1): 30-34
7 Hartschuh W, Schulz T.Merkel cell hyperplasia in chronic radiationdamaged skin: its possible relationship to fibroepithelioma of Pinkus [J]. Cutan Pathol, 1997,24(5): 477-483
8 Martin RC 2nd, Edwards Mj, Cawte TG, et al. Basosquamous carcinoma: analysis of prognistic factors influencing reccurrence [J]. Cancer, 2000, 88(6): 1365-1369
9 Beer TW, Shepherd P, Theak JM.Ber EP4 and epithelial membrane antigen aid distinction of basal cell, squamous cell and basosqumous carcinoma of the skin [J]. Histopathology, 2000, 37(3): 218-223
10 Lao LM, Kumakiri M, Kiyohara T, et al. Sub-populations of melanocytes in pigmented basal cell carcinoma: a quantitative, ultrastructural investigation [J]. L Cutan Pathol, 2001, 28(1): 34-43
11 Giles GG, Marke R, Foley P, et al. Incidence of non-melanocytic skin cancer treated in Australia.Br Med J (clin Res Ed). 1998, 296:13-17
12 Ortonne JP.From actinic keratosis to squmaous cell carcinoma. Br J Dermatol.2002, 146suppl16: 20-23
13 Billeret-Lebranchu V, Martin de lasalle V, et al. Granular cell tumor and congenital epulis. Hischemical and immunohischemical of 58 cases. Arch Anat Cytol Pathol.1999, 47:31-37
14 Motley R, Kersey P, Lawrence C.Multiprofessional guidelines for the management of the patients with primary cutaneous squamous cell carcinoma. Br J Dermatol.2002, 146:18-25
15 Nguyen P, Vin-christian K, Ming ME, et al. Aggressive squamous cell carcinima in persons infected with the human immunodeficiency. Arch Dermatol.2002, 138:758-763
16 Turner RJ Leonard N, Malcolm AJ, et al. A retrospective study of outcome of Mohs’micrographic surgery for cutaneous squmaous cell carcinoma-using formalin fixed sections. Br. J Dermatol. 2000, 142: 752-757
17 Kao GF.Carcinoma arising in Bowen’s desease. Arch Dermatol.1986, 122:1124-1126
18 Khanna M, Fortier-Riberdy G, Smoller B, et al. Reportin tumor thickness for cutaneous squamous cell carcinoma. J Cutan Pathol.2002, 29:321-323
19 Rowe DE, Carroll RJ, Day CLJr, et al. Prognostic factors for local recurrence, metastasis, and survival rates in squmaous cell carcinoma of the skin, ear and lip. Implications for treatment modality selections. J Am Acad Dermatol.1992, 26:976-990
20藤蔚,史同新,曲才杰.PTEN和Survivin在鳞状细胞癌中的表达[J].中国麻风皮肤病杂志,2005, 21(6):438-440
21 Chiodino C, Cesinaro AM, and Ottani D, et al. Communication: expression of the novel inhibitor of apoptosis survivin in normal and neoplastic skin. J Invest Dermatal 1999, 113:415-418
22 Lo Muzio L, Staibano S, Pannoe G, et al. Expression of the apoptosis inhibitor Survivin in the aggressive squamous cell carcinoma. Exp Mol Pathol 2001, 70:249-254
23刘振祥,崔建. P16, P21和cyclinD1mRNA在皮肤鳞状细胞癌中的表达.北京医科大学学报, 1998, 10(5):471-472
24 Shea CR, Menutt NS, Volkeandt M, et al. Over expression of p53 protein in basal cell carcinoma of human skin.[J].Am J Dermatolpathol, 1992, 141:25
25 Rady P, Scinicariello F, Wagner RF, et al. P53 mutations in basal cell carcinomas. Cancer Res, 1992, 52:3804
26 Stephen TJ, Rords J, Silcocks PB, et al. Mutant p53 oncogene expression in keratoacanthoma and squamous cell carcinoma [J]. Br J Dermatol, 1992, 127:566
27 Mcgregor JM, YU CCw, Dublin EA, et al. Aberrant expression of p53 protein tumor-suppressor protein in non-melonoma skin cancer [J]. Br J Dermatol, 1992; 127:463-467
28李慧忠,樊翌明,李顺凡,等.CD44v6和PCNA在皮肤鳞状细胞癌中的表达及其临床意义[J].中国麻风皮肤病杂志, 2004, 20(1):01-03
29田重伟,皮肤鳞状细胞癌中FHIT蛋白的检测及临床意义[J].中国皮肤性病学杂志, 2005, 19(2):68-71
30 Pierccall WE, Goldberg LH, Tainsky MA, et al. Ras gene mutation and amplication in human non-melonoma skin cancers. Mol Carcinog, 1991, 4:196-210
31 Ananthaswamy HN, Price JE, Goldberg LH, et al. Detection and identification of activated oncogenes in human skin cancers occurring on sun-exposed body sites [J]. Cancer Res, 1988, 48:33-41
32 Gart SJ, Bms FJ, Ashkenazi-Kimmel t, et al. Amplification of the c-myc oncogene during progression of radition-induced rat skin tumors [J]. Cancer Res, 1990, 50:3073-3076
33 Zhu WY, Leonardi C, Penney NS.Detection of human papillomavirus DNA in seborheic keratosis by polymerase chain reaction. J Dermatol Sci 1992, 4:166-171
34 Weinstock MA.Epidemiologic investigation of nonmelanoma skin cancer mortality: the Rhode Island Follow-Back study. J invests Dermatol. 1994, 102:6s-9s
35 Lund KA. How often does squamous cell carcinoma of the skin metastasize? Arch Dermatol. 1965, 92:635-637
36 Moler R, Reymann F, Hou-Jensen K, et al. Metastases in dermatological patients with squamous cell carcinoma. Arch Dermatol. 1979, 115:703-703
37 Alam M, Ratner F.Cutaneous squamous cell carcinoma. N Engl J Med. 2001, 344:975-983
38 Dinehart SM. The treatment for actinic keratosis. J Am Acad Dermatol. 2000,42:25-28
39 Rowe DE, Carroll JR, Day Cljr, et al. Prognostic factors of local recurrence, metastasis, and survival rates in squamous cell carcinoma of thr skin, ear, and lip Implication for treatment modality selection. J Am Acad Dermatol.1992, 26:976-990
40 Marcil I, Stern RS.Risk of developing a subsequent nonmelanoma skinscancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol. 2000, 136:1524-1530
41 Miller SJ.The National Comprehensive Cancer Network (NCCN) guides of care for nonmalenoma skin cancers. Dermatol Surg, 2000, 26:289-292
42 Rowe DE, Caroll RJ, DayCLJr, et al. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implication for patient follow-up. J Dermatol Surg Oncol.1989, 15:315-328
43 Lo JS, Snow SN, Reizner GT, et al. Matastatic basal cell carcinoma: report of twelve cases with review of the literature. J Am Acad Dermatol. 1991, 24:725-719
44 Karagas MR.Occurrence of cutaneous basal cell and squamous cell among those with a prior history of skin cancer. The skin carcinoma cancer prevention study group. J Invest Dermatol. 1994, 102: 10s-13s
45 Lindelof B, Sigurgeirsson B, Wall-berg P, et al. Occurrence of other malignancies in 1973 patients with basal cell carcinoma. J Am Acad Dermatol.1991, 25:245-248
1 David Gill, Abe Dorevitch, Robin Marks.The prevalence of seborrheic keratosis in people aged 15 to 30 years, is the term senile keratosis redundant? Arch Dermatol 2000, 136:759-762
2高文天,李春英,黄慧.脂溢性角化病231例临床和病理分析.临床皮肤科杂志2002, 31:279-281
3 Zhu WY, Leonardi C, Penney NS. Detection of human papillomavirus DNA in senile keratosis by polymerase chain reaction. J Dermatol Sci 1992, 4:166-171
4 Yeatman JM, Killenny M, Marks R.The prevalence of seborrheic keratosis in an Australian population: dose exposure to sunlight plays a part in their freguency? British J of Dermatol 1997, 137:411-414
5常建民,吴意平,杨敏.老年性脂溢性角化患者血脂、脂蛋白、载脂蛋白的分析.临床皮肤科杂志2002, 31: 85-86
6 Sloan JB, Jaworsky C.Clinical misdiognosisi of squamous cell carcinoma in situ as seborrheic keratosis. A prospective study. J Dermatol Surg Oncol 1993, 19:413-416
7 Rao BK, Fraaman RC, Paulos EG, et al. The relationship between basal cell epithelioma and seborrheic kerotosis. J Dermatol Surg oncol1994: 20:761-764
8 Urano Y, Oura H, Sakaki A, et al.immunohistological analysis of P53 expression in human skin tumors. J Dermatol Sci.1993, 5:212-213
9 Nakagawa K, Ramamura Kmaeda S, et al. Bcl-2 expression of epidermal keratinocytic disease. Cancer 1994, 74:1720-1724
10 Tanikawa E, Mori D, Harchisuka H, et al. Expression of ras proto-oncogene related protein P21 in normal human skin and cutaneous tumors. Acta Histochem.1992, 93:282-289
11王晓彦,萨娜,王泽民,等.鳞癌和脂溢性角化病DNA倍体图像定量分析.中国皮肤性病学杂志2000, 14: 88-89
12 Nakamura H, Hirotus S.Adachi S, et al. Clonal nature of seborrheickeratosis demonstrated using the polymorphism of the human androgen receptor locusas a marker. J invests Dermatol 2001, 116:506-5510
13 Grob JJ, Rava MC, Gouvernet J, et al. The relation between seborrheic keratosis and malignant solid tumors. A case-control study. Acta Derm Venereol 1991, 71:166-169
14 Nakamura H, Hirota S, Adachi S, et al. Clonal nature of seborrheic keratosis demonstrated by using the polymorphism of the human androgen receptor locus as a marker. J invests Dermatol.2001, 116:506-510
15 Pesce D, Scalora S, Apoptosis in the area of squamous differentiation irritated seborrheic keratosis. J cuta Pathol 2000, 27: 121-123
16李澄,周红,樊小妹,等. EGF、EGFr在脂溢性角化病组织中的表达.临床皮肤科杂志2001, 30:225-226
17彭程,施岩,路麒,张莉. P16、P21WAF1/CIP1、PCNA和Cyclin E在脂溢性角化病中的表达及其意义[J].中国麻风皮肤病杂志.2007, 23(8):658-660
18李颖,何威,林自华,等.脂溢性角化病皮损的表皮中TGF-?受体表达下调[J].第三军医大学学报, 2006, 28(3):239-242
19杨扬,何威,何云志,等.脂溢性角化病、基底细胞癌和鳞状细胞癌中几种Smad蛋白表达的检测[J].临床皮肤科杂志, 2007, 36(7):423-425
20 LEE SC, LEE JB, Seo JJ, et al. Expression of trichohyalin in dermatological disorder. A comparative study with involucrin and filaggrin immunohisto chemical staining. Acta Derm Venereol1999, 79:97
21 Sumitono S, Kumasa S, Iwai Y, et al. Involucrin expression in epithelial tumor of oral ang pharyngeal mucosa and skin. Ora surg oral Med Oral Pathol, 1986, 62:63
22 Fujisawa H, Naito Y, Muraki R, et al. Diferentiation disorders of keratinocytes in seborrheic keratosis (acantholic type). J Dermatol, 1991, 18:635-638
23 Luzi P, Miracco C, Del Vecchio MT.Stereological study of desmosomes in basal cellcarcinoma and seborrheic keratosis. J Submicrosc Cytol, 1987, 19:337-343
24 Kwon OS, Hwang EJ, and Bae JH, et al. seborrheic keratosis in the Korean males: causative role of sunlight. Photodermatol photoimmuol photomed, 2003, 19(2): 73-80
25 Manaka L, Kadono S, Kawashima M, et al. The mechanism of hyperpigmentation in seborrheic keratosis involves the high expression of endothelin-converting enzyme-1 alpha and TNF-alpha, which stimulate secretionof endothelin1. Br J Dermatol, 2001, 145:895-903
26 Wu juan,Sheng wan-xiang.Expression of ET-1,ECE-1 and YNF-αin the lesions of seborrheic keratosis.China J Dermatol, 2009, 42(2): 143
27 Asagami C, Muto M, Hirota T, et al. Anti-tumor effects of 1,25-dihydroxyvitaminD3 [1,25(OH)2D3] in seborrheic keratosis. J Investing Dermatol Symp Proc.1996, 1:94-96
28 Benodi D, Pezzarossa E, Alinovi A, et al. Retinoic acid and 5-Fu mixture in the topical treatment of several skin deseases. Ateneo Parmense Acta Biomed. 1980: 51:182-192
29 Feuerman EJ, Katzenelson V, Halevy S.olcoderm in the treatment of solar and seborrheic keratosis. Dermatologica, 1984:168Suppl 1:33-35
30 Broekaert D, Leigh IM, Lane EB, et al. An immunohischemical and histochemical study of cytokeratin, involucrin and transglutaminase in seborrhoeic keratosis. Arch Dermatol Res.1993, 285:482-490